Nanobiotix and Johnson & Johnson reported early data from the CONVERGE study, a randomized Phase II clinical trial evaluating JNJ-1900 (NBTXR3) as a radioenhancer in patients with stage 3 inoperable non-small cell lung cancer (NSCLC). The results were posted at the 2026 European Lung Cancer Conference via a poster presentation and accompanying press release.

The company said early efficacy data from seven evaluable patients at first disease assessment following concurrent chemoradiotherapy — and before consolidative anti-PD-L1 therapy — showed an objective response rate of 71.4% and a disease control rate of 100%, compared with an estimated historical benchmark ORR of 45%–50%. The intratumoral injection procedure was reported to have an acceptable safety profile, with no serious treatment-emergent adverse events observed, and the company said it did not adversely affect patients’ ability to continue planned therapy.

The CONVERGE study is a Johnson & Johnson-sponsored, randomized, open-label, active-controlled Phase II trial in patients with unresectable stage III NSCLC. The study evaluates JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle administered as a one-time intratumoral injection, in combination with concurrent chemoradiotherapy followed by consolidative immunotherapy with durvalumab. Public trial registry materials identify objective response rate (ORR) by independent central review as the primary endpoint. The data are from a subset of seven patients at an early assessment. Full trial details can be found on allsci.com.

JNJ-1900 (NBTXR3) consists of functionalized hafnium oxide nanoparticles designed to amplify local radiation dose deposition within tumors when activated by radiotherapy. The current standard of care in unresectable stage III NSCLC is concurrent platinum-based chemoradiotherapy followed by consolidation durvalumab, which demonstrated a 24-month overall survival rate of 66.3% versus 55.6% for placebo in the Phase III PACIFIC trial. Cross-trial comparisons are limited by differences in study design, duration, and patient populations.